Cost of Patients With Hemophilia A and High-Titer Inhibitors in Colombia

•There have been studies around the world that have estimated the cost of hemophilia A with inhibitors. Nevertheless, in middle- and low-income countries in the Latin American context, it is important to determine the actual cost of an illness to guide related public policies.•In Colombia, hemophilia is considered a high-cost disease, and the institutions involved in its treatment systematically collect and analyze information related to the clinical process. Nevertheless, this is the first study that defines the base cases for patients with hemophilia A with high-titer inhibitors in Colombia (a middle-income country), and based on these cases, the total and the average costs of this disease for Colombia were estimated ($44 905 252 and $498 947, respectively). The costs are expressed in USD (1 USD = $2900 Colombian pesos, average January 2018 to October 2018).•Hemophilia A with high-titer inhibitors is a disease that generates significant pressure on the Colombian health system (a middle-income country), mainly linked to the cost of the factor concentrates and bypassing agents required for treatment. This evidence will allow Colombia (and similar countries) to know the real economic effort that results from this disease, and with this information, stakeholders, including policy makers, may provide input based on evidence for decision making.